| Nicole Jiam, MD | |
|
243 Charles St, Boston, MA 02114-3096 | |
| (617) 573-3654 | |
| Not Available |
| Full Name | Nicole Jiam |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Location | 243 Charles St, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831513225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 1014504 (Massachusetts) | Primary |
| Entity Name | Massachusetts Eye And Ear Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932574332 PECOS PAC ID: 4486540275 Enrollment ID: O20040227000123 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
In order to sing or speak, around one hundred different muscles in our chest, neck, jaw, tongue, and lips must work together to produce sound. Beckman researchers investigate how all these mechanisms effortlessly work together-and how they change over time.
The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas.
iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.
The recent shake-up of the global ultrasound market following the merger of Aloka and Hitachi Medical, and the recently announced acquisition of Medison by Samsung Electronics, points to an intriguing future. Research Analyst Stephen Holloway, author of InMedica's acclaimed "World Market for Ultrasound Imaging Equipment – 2010 edition" assesses the repercussions.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Jiam, MD 243 Charles St, Boston, MA 02114-3096 Ph: (617) 573-3654 | Nicole Jiam, MD 243 Charles St, Boston, MA 02114-3096 Ph: (617) 573-3654 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
In order to sing or speak, around one hundred different muscles in our chest, neck, jaw, tongue, and lips must work together to produce sound. Beckman researchers investigate how all these mechanisms effortlessly work together-and how they change over time.
The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas.
iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.
The recent shake-up of the global ultrasound market following the merger of Aloka and Hitachi Medical, and the recently announced acquisition of Medison by Samsung Electronics, points to an intriguing future. Research Analyst Stephen Holloway, author of InMedica's acclaimed "World Market for Ultrasound Imaging Equipment – 2010 edition" assesses the repercussions.
› Verified 4 days ago
Dr. Steven D. Rauch, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Elliott D. Kozin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-6545 | |
Katherine Nicole Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 830 Harrison Ave Ste 1400, Boston, MA 02118 Phone: 617-638-8124 | |
Yoon Sun Chun, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Brigham And Women's Hospital Dept Of Plastic Surgery, Boston, MA 02115 Phone: 617-732-8181 Fax: 617-983-4534 | |
Jaimie Derosa, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 91 Newbury St, Suite 300, Boston, MA 02116 Phone: 617-262-8000 Fax: 617-262-8002 | |
Dr. Usama M Aboelkheir, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Smc8, Boston, MA 02135 Phone: 617-789-5004 Fax: 617-779-6481 | |
Phillip C Song, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3557 |